A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus
Not yet recruiting
Eli Lilly and Company
The main purpose of this study is to learn more about a new formulation of insulin lispro
when given by an insulin pump to participants with type 1 diabetes mellitus. The study will
investigate how the body processes the drug and how the drug affects the body. Information
about side effects will be collected. The study will last from six to 12 weeks for each
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
The purpose of the study is to compare the effect in blood sugar control between Lantus and
twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a
multiple daily injection setting with fast acting insulin (Lispro)
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
Novo Nordisk A/S
This trial is conducted in the United States of America (USA). It is demonstrated that
intensive insulin therapy resulting in good glycaemic control can reduce or delay the
incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an
ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin
injection (CSII) therapy in the pediatric and adolescent age population. This trial compares
the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered
by CSII in children and adolescents with type 1 diabetes.
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and
effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents
with type 1 diabetes mellitus.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.